**Elevated Treasury yields near 5.3% following the Fed’s September rate increase and selective investor focus on profitability have tempered enthusiasm for large 2026 IPOs, even as smaller biotechs and SPACs continue to price.** With only weeks remaining before year-end, Anthropic’s planned mid-November debut at a potential $1.8–2 trillion valuation stands as the clearest near-term catalyst, while OpenAI has shifted toward another large private round rather than a 2026 listing. Broader pipeline data show 254 U.S. IPOs year-to-date through mid-October, yet mega-cap names face compressed marketing windows and valuation scrutiny amid geopolitical and election uncertainty. Market-implied odds on Polymarket reflect these tight timelines, with probabilities for specific issuers hinging on successful roadshows, regulatory clearance, and sustained equity demand before December 31.